ReviewEcho research and practice2018
Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?
Review in Echo research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Integrated NEK7-inflammasome and platelet transcriptomic signature generates mechanistic hypotheses in heart failure.PloS one · 2026Article
- Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency.Diagnostics (Basel, Switzerland) · 2025Article
- Assessment of breathlessness: a cardiologist's perspective.Breathe (Sheffield, England) · 2025Review
- The clinical classification of patients with acute heart failure at emergency department and its relation with management and outcome: a cross sectional study from Syria.BMC cardiovascular disorders · 2025Article
- Heart Failure with Preserved Ejection Fraction in Egypt: An Expert Opinion.Global heart · 2025Review
- Early diagnostic and prognostic value of myocardial strain derived from cardiovascular magnetic resonance in patients with cardiac amyloidosis.Cardiovascular diagnosis and therapy · 2023Article
- Subclinical and latent cardiac dysfunction in obstructive sleep apnea and effectiveness of continuous positive airway pressure.Sleep & breathing = Schlaf & Atmung · 2023Article
- Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists.Cardiology and therapy · 2023Review
- Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Longitudinal CMR assessment of cardiac global longitudinal strain and hemodynamic forces in a mouse model of heart failure.The international journal of cardiovascular imaging · 2022Article
- N-terminal pro brain natriuretic peptide reference values in community-dwelling older adults.ESC heart failure · 2022Article
- Right Ventricular Longitudinal Strain in Patients with Heart Failure.Diagnostics (Basel, Switzerland) · 2022Review
- Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice.Irish journal of medical science · 2022Review
- Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Metabolic syndrome and heart failure: mechanism and management.Medicine and pharmacy reports · 2021Review
- Prediction of cardiac events using fully automated GLS and BNP titers in patients with known or suspected heart failure.PloS one · 2020Article
- Left ventricular function monitoring in heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a threat to public health. Heterogeneities in aetiology and phenotype complicate the diagnosis and management of HF. This is especially true when considering HF with preserved ejection fraction (HFpEF), which makes up 50% of HF cases. Natriuretic peptides may aid in establishing a working diagnosis in patients suspected of HF, but echocardiography remains the optimal choice for diagnosing HF. Echocardiography provides important prognostic information in both HF with reduced ejection fraction (HFrEF) and HFpEF. Traditionally, emphasis has been put on the left ventricular ejection fraction (LVEF). LVEF is useful for both diagnosis and prognosis in HFrEF. However, echocardiography offers more than this single parameter of systolic function, and for optimal risk assessment in HFrEF, an echocardiogram evaluating systolic, diastolic, left atrial and right ventricular function is beneficial. In this assessment echocardiographic modalities such as global longitudinal strain (GLS) by 2D speckle-tracking may be useful. LVEF offers little value in HFpEF and is neither helpful for diagnosis nor prognosis. Diastolic function quantified by E/e' and systolic function determined by GLS offer prognostic insight in HFpEF. In HFpEF, other parameters of cardiac performance such as left atrial and right ventricular function evaluated by echocardiography also contribute with prognostic information. Hence, it is important to consider the entire echocardiogram and not focus solely on systolic function. Future research should focus on combining echocardiographic parameters into risk prediction models to adopt a more personalized approach to prognosis instead of identifying yet another echocardiographic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.